Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study.

Breast Cancer Res Treat · 2026 · PMC12929343 · PMID 41729316

Europe PMC DOI

hedged sentence

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

did not reach statistical significancep = 0.084so close (0.05 < p ≤ 0.1)

Patients who experienced an immune-related adverse event (iRAE) also had higher odds of developing a pCR, although this association did not reach statistical significance (OR 5.15; 95% CI 0.80–33.13; p = 0.084) (Table 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.